Diffuse bone increase uptake of gallium-67 related to cyclophosphamide and recombinant human granulocyte-colony stimulating factor (rHuG-CSF) administration.
Ruíz-Hernández
G
G
Clinic Universitary Hospital, University of Valencia, Spain.
Solano-Vercet
C
C
Terol-Castera
M J
MJ
Rodilla Sala
E
E
Castillo-Pallarés
F J
FJ
Balaguer-Martínez
J V
JV
Mateo-Navarro
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005710:Gallium Radioisotopes / Q000493:pharmacokinetics*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011877:Radionuclide Imaging; D011994:Recombinant Proteins; D014018:Tissue Distribution
D005710:Gallium Radioisotopes; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin; D008775:Methylprednisolone